Cite
HARVARD Citation
Kimbung, S. et al. (2018). Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. International journal of cancer. 142 (3), pp. 618-628. [Online].